Top

Published in:

Open Access 01-04-2016 | Contrast Media

ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents

Authors: E. Neri, M. A. Bali, A. Ba-Ssalamah, P. Boraschi, G. Brancatelli, F. Caseiro Alves, L. Grazioli, T. Helmberger, J. M. Lee, R. Manfredi, L. Martì-Bonmatì, C. Matos, E. M. Merkle, B. Op De Beeck, W. Schima, S. Skehan, V. Vilgrain, C. Zech, C. Bartolozzi

Published in: European Radiology | Issue 4/2016

Abstract

Objectives

To develop a consensus and provide updated recommendations on liver MR imaging and the clinical use of liver-specific contrast agents.

Methods

The European Society of Gastrointestinal and Abdominal Radiology (ESGAR) formed a multinational European panel of experts, selected on the basis of a literature review and their leadership in the field of liver MR imaging. A modified Delphi process was adopted to draft a list of statements. Descriptive and Cronbach’s statistics were used to rate levels of agreement and internal reliability of the consensus.

Results

Three Delphi rounds were conducted and 76 statements composed on MR technique (n = 17), clinical application of liver-specific contrast agents in benign, focal liver lesions (n = 7), malignant liver lesions in non-cirrhotic (n = 9) and in cirrhotic patients (n = 18), diffuse and vascular liver diseases (n = 12), and bile ducts (n = 13). The overall mean score of agreement was 4.84 (SD ±0.17). Full consensus was reached in 22 % of all statements in all working groups, with no full consensus reached on diffuse and vascular diseases.

Conclusions

The consensus provided updated recommendations on the methodology, and clinical indications, of MRI with liver specific contrast agents in the study of liver diseases.

Key points

• Liver-specific contrast agents are recommended in MRI of the liver.

• The hepatobiliary phase improves the detection and characterization of hepatocellular lesions.

• Liver-specific contrast agents can improve the detection of HCC.

X.X. refers to a panelist who left the panel after the third round.

Bellin MF, Vasile M, Morel-Precetti S (2003) Currently used non-specific extracellular MR contrast media. Eur Radiol 13:2688–2698CrossRefPubMed

Balci NC, Semelka RC (2005) Contrast agents for MR imaging of the liver. Radiol Clin N Am 43:887–898CrossRefPubMed

Erturk SM, Alberich-Bayarri A, Herrmann KA, Marti-Bonmati L, Ros PR (2009) Use of 3.0-T MR imaging for evaluation of the abdomen. Radiographics 29:1547–1563CrossRefPubMed

Kudo M (2011) Diagnostic imaging of hepatocellular carcinoma: recent progress. Oncology 81:73–85CrossRefPubMed

Zech CJ, Bartolozzi C, Bioulac-Sage P et al (2013) Consensus report of the fifth international forum for liver MRI. AJR Am J Roentgenol 201:97–107CrossRefPubMed

Choi JY, Lee JM, Sirlin CB (2014) CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology 272:635–654, reviewer 2, comment 24CrossRefPubMedPubMedCentral

van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE (1999) Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther 290:153–157PubMed

Seale MK, Catalano OA, Saini S, Hahn PF, Sahani DV (2009) Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics 29:1725–1748CrossRefPubMed

Semelka RC, Helmberger TK (2001) Contrast agents for MR imaging of the liver. Radiology 218:27–38CrossRefPubMed

10.

Ringe KI, Husarik DB, Sirlin CB, Merkle EM (2010) Gadoxetate disodium–enhanced MRI of the liver: Part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR 195:13–28CrossRefPubMed

11.

Goodwin MD, Dobson JE, Sirlin CB, Lim BG, Stella DL (2011) Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents. RadioGraphics 31:1547–1568CrossRefPubMed

12.

Van Beers BE, Pastor CM, Hussain HK (2012) Primovist, Eovist: what to expect? J Hepatol 57:421–429CrossRefPubMed

13.

Guglielmo FF, Mitchell DG, Gupta S (2014) Gadolinium contrast agent selection and optimal use for body MR imaging. Radiol Clin N Am 52:637–656CrossRefPubMed

14.

Ronot M, Vilgrain V (2014) Hepatocellular carcinoma: diagnostic criteria by imaging techniques. Best Pract Res Clin Gastroenterol 28:795–812CrossRefPubMed

15.

Cogley JR, Miller FH (2014) MR imaging of benign focal liver lesions. Radiol Clin N Am 52:657–682CrossRefPubMed

16.

Hope TA, Ohliger MA, Qayyum A (2014) MR imaging of diffuse liver disease: from technique to diagnosis. Radiol Clin N Am 52:709–724CrossRefPubMed

17.

Graham B, Regehr G, Wright JG (2003) Delphi as a method to establish consensus for diagnostic criteria. J Clin Epidemiol 56:1150–1156CrossRefPubMed

18.

Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64:383–394CrossRefPubMed

19.

Bravo G, Potvin L (1991) Estimating the reliability of continuous measures with Cronbach's alpha or the intraclass correlation coefficient: toward the integration of two traditions. J Clin Epidemiol 44:381–390CrossRefPubMed

20.

Cronbach L (1951) Coefficient alpha and the internal structure of tests. Psychometrika 16:3CrossRef

21.

Ramalho M, Altun E, Herédia V, Zapparoli M, Semelka R (2007) Liver MR imaging: 1.5T versus 3T. Magn Reson Imaging Clin N Am 15:321–347CrossRefPubMed

22.

Merkle EM, Dale BM, Paulson EK (2006) Abdominal MR imaging at 3T. Magn Reson Imaging Clin N Am 14:17–26CrossRefPubMed

23.

von Falkenhausen MM, Lutterbey G, Morakkabati-Spitz N et al (2006) High-field-strength MR imaging of the liver at 3.0 T: intraindividual comparative study with MR imaging at 1.5 T. Radiology 241:156–166 (reviewer 2, comment 15)CrossRef

24.

Chang JM, Lee JM, Lee MW et al (2006) Superparamagnetic iron oxide-enhanced liver magnetic resonance imaging: comparison of 1.5 T and 3.0 T imaging for detection of focal malignant liver lesions. Investig Radiol 41:168–174 (reviewer 2, comment 15)CrossRef

25.

Gupta RT, Iseman CM, Leyendecker JR, Shyknevsky I, Merkle EM, Taouli B (2012) Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium. AJR Am J Roentgenol 199:35–43 (reviewer 4, comment 2)CrossRefPubMed

26.

Karam AR, Shankar S, Surapaneni P, Kim YH, Hussain S (2010) Focal nodular hyperplasia: central scar enhancement pattern using gadoxetate disodium. J Magn Reson Imaging 32:341–344 (reviewer 4, comment 2)CrossRefPubMed

27.

Park Y, Kim SH, Kim SH et al (2010) Gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI versus gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI for preoperatively detecting hepatocellular carcinoma: an initial experience. Korean J Radiol 11:433–440 (reviewer 4, comment 2)CrossRefPubMedPubMedCentral

28.

Jeong WK, Kim YK, Song KD, Choi D, Lim HK (2013) The MR imaging diagnosis of liver diseases using gadoxetic acid: emphasis on hepatobiliary phase. Clin Mol Hepatol 19:360–366 (reviewer 2, comment 24)CrossRefPubMedPubMedCentral

29.

Kim HJ, Kim BS, Kim MJ et al (2013) Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate. Reson Imaging 37:903–938 (reviewer 2, comment 24)CrossRef

30.

Ba-Ssalamah A, Qayyum A, Bastati N, Fakhrai N, Herold CJ, Caseiro Alves F (2014) P4 radiology of hepatobiliary diseases with gadoxetic acid-enhanced MRI as a biomarker. Expert Rev Gastroenterol Hepatol 8:147–160CrossRefPubMed

31.

Grazioli L, Bondioni MP, Haradome H et al (2012) Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. Radiology 262:520–529CrossRefPubMed

32.

Grazioli L, Morana G, Kirchin MA, Schneider G (2005) Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenatedimeglumine-enhanced MR imaging: prospective study. Radiology 236:166–177 (reviewer 4, comment 4)CrossRefPubMed

33.

Haimerl M, Wächtler M, Platzek I et al (2013) Added value of Gd-EOB-DTPA-enhanced Hepatobiliary phase MR imaging in evaluation of focal solid hepatic lesions. BMC Med Imaging 13:41 (reviewer 2, comment 24)CrossRefPubMedPubMedCentral

34.

Morana G, Grazioli L, Kirchin MA et al (2011) Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenatedimeglumine administration. Investig Radiol 46:225–239 (reviewer 4, comment 5)CrossRef

35.

Scharitzer M, Ba-Ssalamah A, Ringl H, Kölblinger C, Grünberger T, Weber M, Schima W (2013) Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation. Eur Radiol 23:2187–2196CrossRefPubMed

36.

Kim YK, Park G, Kim CS, Yu HC, Han YM (2012) Diagnostic efficacy of gadoxetic acid-enhanced MRI for the detection and characterisation of liver metastases: comparison with multidetector-row CT. Br J Radiol 85:539–547CrossRefPubMedPubMedCentral

37.

Han NY, Park BJ, Sung DJ et al (2014) Chemotherapy-induced focal hepatopathy in patients with gastrointestinal malignancy: gadoxetic acid–enhanced and diffusion-weighted MR Imaging with clinical-pathologic correlation. Radiology 271:416–425CrossRefPubMed

38.

Péporté AR, Sommer WH, Nikolaou K, Reiser MF, Zech CJ (2013) Imaging features of intrahepatic cholangiocarcinoma in Gd-EOB-DTPA-enhanced MRI. Eur J Radiol 82:101–106CrossRef

39.

Park HJ, Kim YK, Park MJ, Lee WJ (2013) Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma. Abdom Imaging 38:793–801CrossRefPubMed

40.

Verloh N, Haimerl M, Rennert J et al (2013) Impact of liver cirrhosis on liver enhancement at Gd-EOB-DTPA enhanced MRI at 3 Tesla. Eur J Radiol 82:1710–1715CrossRefPubMed

41.

Phongkitkarun S, Limsamutpetch K, Tannaphai P, Jatchavala J (2013) Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients. World J Gastroenterol 19:8357–8365CrossRefPubMedPubMedCentral

42.

Haimerl M, Verloh N, Fellner C et al (2014) MRI-based estimation of liver function: Gd-EOB-DTPA-enhanced T1 relaxometry of 3T vs. the MELD score. Sci Rep 4:5621CrossRefPubMedPubMedCentral

43.

Verloh N, Haimerl M, Zeman F et al (2014) Assessing liver function by liver enhancement during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MRI at 3 Tesla. Eur Radiol 24:1013–1019CrossRefPubMed

44.

Cereser L, Furlan A, Bagatto D et al (2010) Comparison of portal venous and delayed phases of gadolinium-enhanced magnetic resonance imaging study of cirrhotic liver for the detection of contrast washout of hypervascular hepatocellular carcinoma. J Comput Assist Tomogr 34:706–711 (reviewer 4, comment 3)CrossRefPubMed

45.

Bartolozzi C, Battaglia V, Bargellini I et al (2013) Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers. Abdom Imaging 38:290–296CrossRefPubMed

46.

Yu MH, Kim JH, Yoon JH et al (2014) Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging. Radiology 271:748–760CrossRefPubMed

47.

Granito A, Galassi M, Piscaglia F et al (2013) Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study. Aliment Pharmacol Ther 37:355–363 (reviewer 3, comment 5)CrossRefPubMed

48.

Kitajima K, Yoshikawa T, Seo Y et al (2011) A case of Budd-Chiari syndrome: Gd-EOB-DTPA-enhanced MR findings. Magn Reson Imaging 29:579–583CrossRefPubMed

49.

Shin NY, Kim MJ, Lim JS et al (2012) Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases. Eur Radiol 22:864–871CrossRefPubMed

50.

Lee NK, Kim S, Lee JW et al (2009) Biliary MR imaging with Gd-EOB-DTPA and its clinical applications. Radiographics 29:1707–1724CrossRefPubMed

51.

Boraschi P, Donati F (2013) Biliary-enteric anastomoses: spectrum of findings on Gd-EOB-DTPA-enhanced MR cholangiography. Abdom Imaging 38:1351–1359CrossRefPubMed

52.

Boraschi P, Donati F (2014) Postoperative biliary adverse events following orthotopic liver transplantation: assessment with magnetic resonance cholangiography. World J Gastroenterol 20:11080–11094CrossRefPubMedPubMedCentral

Title: ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents
Authors: E. Neri
M. A. Bali
A. Ba-Ssalamah
P. Boraschi
G. Brancatelli
F. Caseiro Alves
L. Grazioli
T. Helmberger
J. M. Lee
R. Manfredi
L. Martì-Bonmatì
C. Matos
E. M. Merkle
B. Op De Beeck
W. Schima
S. Skehan
V. Vilgrain
C. Zech
C. Bartolozzi
Publication date: 01-04-2016
Publisher: Springer Berlin Heidelberg
Published in: European Radiology / Issue 4/2016
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-015-3900-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents

Abstract

Objectives

Methods

Results

Conclusions

Key points

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objectives

Methods

Results

Conclusions

Key points

Please log in to get access to this content

Other articles of this Issue 4/2016

US characteristics for the prediction of neoplasm in gallbladder polyps 10 mm or larger

Comparison of optimised endovaginal vs external array coil T2-weighted and diffusion-weighted imaging techniques for detecting suspected early stage (IA/IB1) uterine cervical cancer

Diffusion tensor imaging in patients with obstetric antiphospholipid syndrome without neuropsychiatric symptoms

MRI features of peripheral traumatic neuromas

Volume-assisted estimation of liver function based on Gd-EOB-DTPA–enhanced MR relaxometry

Thoracic and abdominal aortic diameters in a general population: MRI-based reference values and association with age and cardiovascular risk factors